MetLife Investment Management’s Tyra Biosciences TYRA Stock Holding History

MetLife Investment Management’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$536K	Sell	13,993 -1,363	-9%	-$44.1K	﹤0.01%	1729
2025 Q4	$404K	Buy	15,356 +725	+5%	+$13.3K	﹤0.01%	1891
2025 Q3	$205K	Hold	14,631	–	–	﹤0.01%	2303
2025 Q2	$140K	Buy	14,631 +2,424	+20%	+$23K	﹤0.01%	2374
2025 Q1	$114K	Hold	12,207	–	–	﹤0.01%	2469
2024 Q4	$170K	Hold	12,207	–	–	﹤0.01%	2380
2024 Q3	$287K	Hold	12,207	–	–	﹤0.01%	2089
2024 Q2	$195K	Buy	12,207 +4,505	+58%	+$77.5K	﹤0.01%	2260
2024 Q1	$126K	Hold	7,702	–	–	﹤0.01%	2432
2023 Q4	$107K	Hold	7,702	–	–	﹤0.01%	2583
2023 Q3	$106K	Hold	7,702	–	–	﹤0.01%	2552
2023 Q2	$131K	Hold	7,702	–	–	﹤0.01%	2527
2023 Q1	$124K	Buy	+7,702	New	+$91.6K	﹤0.01%	2463

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

MetLife Investment Management's TYRA Position: Q1 2026 in Review

MetLife Investment Management reduced its Tyra Biosciences (TYRA) stake by 8.9% in Q1 2026, selling an estimated $44.1K and leaving 13,993 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #1729.

MetLife Investment Management first reported a position in TYRA in Q1 2023 and has held it in 13 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

MetLife Investment Management held 13,993 shares of Tyra Biosciences worth $536K as of Q1 2026.
MetLife Investment Management sold 1,363 Tyra Biosciences shares in Q1 2026, an estimated $44.1K.
Tyra Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1729 holding.
MetLife Investment Management first reported a position in Tyra Biosciences in Q1 2023 and has held it in 13 quarters since.
164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.